Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b studyTHE WOODLANDS, Texas, Sept. 17, 2025 ...

SPONSORED – Neuropathy is becoming a bigger problem for more people than ever before. If you’re suffering from stabbing pain, numbness, tingling or a burning sensation in your arms, legs, hands or ...

One Oklahoma Nurse Practitioner is trying to provide relief for patients by using a drug-free option. It’s approved by the FDA, and after Congress implemented the No Pain Act in January of ...

Mercy Family Health announces a new treatment for peripheral neuropathy is available in DuBois, PA. Restorative Health Care ...

For years I have suffered with electric shock sensations in my left big toe. I can go for months without it happening, then ...

July 24, 2025 – The FDA has approved a new treatment as the first and only skin cream for a specific type of hand eczema that affects about 1 in every 10 people globally. The cream, sold under the ...

If you’re battling the burning and tingling of peripheral neuropathy, especially Diabetes-related or Lyme-related or ...

For people suffering from the burning, tingling and shooting pain of neuropathy, current treatments are limited and often ...

Separately, Lexicon will also present a poster entitled “Study Design and Rationale of PROGRESS: Pilavapadin in a Phase 2b, Dose-ranging, Double-blind, Placebo-controlled Study in Diabetic Peripheral ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by ...

(AP) - Rudy Giuliani said Tuesday he experienced “more pain than I ever felt” after a car crash last weekend but expects to recover fully, making his first public remarks on video about the rear-end ...

We’re a media company. We promise to tell you what’s new in the parts of modern life that matter. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis ...